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ABSTRACT 
Multiple myeloma (MM) is clonal disorder of terminally differentiated B cells. In some 
cases premalignant patient’s state is monoclonal gammopathy of undetermined 
significance (MGUS).  Neoplastic plasma cells in both entities carry multiple and 
complex chromosomal abnormalities that make understanding of the disease 
development difficult. New insight in malignant mechanisms that underlay multiple 
myeloma may come from FOXP1 analysis in neoplastic plasma cells. FOXP1 is known 
to be important for B-cell maturation and differentiation and could have significant role in 
plasma cell tumors. 
This is an analysis of FOXP1 protein presence and FOXP1 gene abnormalities in 13 
cases of MGUS and 60 case of MM. 
Our results have shown that FOXP1 protein is expressed in neoplastic plasma cells, 
unlike in their normal counterparts, and that additional FOXP1 gene copies could be 
found in both MGUS and MM. 
Based on FOXP1 presence in MM and its role in diffuse large B-cell lymphoma and 
MALT type lymphoma, we speculate that FOXP1 might have important role for in 
plasma cell neoplasm.  
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INTRODUCTION 
Multiple myeloma (MM) is clonal disorder of antibody-secreting terminally differentiated 
B cells, plasma cells that home to and expand multifocally in the bone marrow. 1 In some 
patients the associated precursor condition for MM is monoclonal gammopathy of 
undetermined significance (MGUS). 2  
Considering MM tumor cells have complex genetic abnormalities which make 
understanding of a disease difficult, new insights on oncogenetic changes are needed. 
One of possible players in disease development is FOXP1. FOXP1 protein is known to 
be upregulated after the B-cell activation; it is expressed in mature B-lymphocytes, but 
not in normal plasma cells, and is connected with B-cell proliferation and differentiation. 
3-6
 It is explored in DLBCL and MALT lymphomas where it has a connection to 
prognosis. 7-10 In this case-series study we show FOXP1 gene abnormalities as well as 
FOXP1 protein presence in neoplastic plasma cells.  
PATIENTS AND METHODS 
Patients 
60 formalin fixed, paraffin embedded bone marrow trephines and/or bone marrow 
aspirate smears taken from patients with MM and 13 formalin fixed, paraffin embedded 
bone marrow trephines and/or bone marrow aspirate smears taken from patients with 
MGUS were analyzed. Immunohistochemical data of characteristic protein expression 
analysis as well as data about most common gene aberrations obtained by FISH 
method in MM were available for all patients, except data about del(13), which were 
available only for 26 MM and four MGUS patients (Table 1). MM group consisted of 30 
females and 30 males, median age 68 years. 39 MM cases had non-diffuse and 21 had 
diffuse type of bone marrow infiltration (Figure 1a and b). 44 MM cases had low grade 
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plasma cells and 16 had high grade plasma cells (Figure 1c and d). MGUS group 
consisted of six females and seven males, median age 67 years. All samples were 
taken at the time of the diagnosis. Histological samples were routinely processed with 
HE, Giemsa and assessed by a qualified pathologists (AŠ and MD). Final diagnoses 
were made by hematologists (DRK and RA) in University Hospital 'Merkur' and 
University Hospital ‘Dubrava’ according to World Health Organization criteria. 1 All MM 
patients had at least one major and one minor or three minor criteria including marrow 
plasamcytosis between 10 and 30% and M-component present less than 3.5 g/dl IgG 
and 2g/dl IgA in serum or 1g/24h of BJ protein in urine. MGUS patients had less M-
component than MM patients, presented less than 10% of bone marrow plasmacytosis, 
showed no bone lesions and had no myeloma related symptoms. 
This study is part of a project approved by the Medical School Ethics Committee, 
University of Zagreb, Croatia. 
 
Methods 
Immunostaining 
Immunostaining was performed on 4 µm thick; formalin fixed paraffin embedded bone 
marrow trephine sections using a LSAB/HRP kit (Dako, Denmark), according to the 
manufacturer’s instructions. The JC12 anti-FOXP1 antibody was acquired from Dr. 
Alison Banham, Oxford, UK. 
Fluorescent in situ hybridization (FISH)   
FISH analysis for defining aberrations involving the FOXP1 locus was performed on 4 
µm thick, formalin fixed paraffin embedded bone marrow trephine sections according to 
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the protocol described by Ventura et al. 11 (http://jmd.amjpathol.org). FOXP1 aberrations 
were detected with the previously described break apart probe. 12  
Statistics 
χ
2
 test was calculated in STATISTICA7 (StatSoft Pacific Pty Ltd., Melbourne, Australia). 
The level of statistical significance was set at 0.05. 
RESULTS 
Immunostaining 
JC12 staining was present in one MGUS (Figure 2a) and 12 MM (Figure 2b) cases 
(Table 2). Cases were regarded as positive if more than 30% of neoplastic plasma cells 
were immunohistochemicaly positive for the JC12 antibody. 
Fluorescent in situ hybridization  
Aberrations involving the FOXP1 locus were observed in five MGUS (all cases with one 
additional fused signal) and 24 MM (20 cases with one additional fused signal, one case 
with four fused signals, three cases with ≥5 fused signals) cases (Table 2).  
Statistics 
MGUS 
FOXP1 protein expression and/or FOXP1 gene changes showed no statistical 
significance when compared with available data listed in Table 1. 
MM 
FOXP1 gene aberrations showed statistical significance when compared with bone 
marrow infiltration. FOXP1 locus showed additional copies in cases with diffuse bone 
marrow infiltration (P=0.000) (Table 3).  Significant results were also obtained between 
FOXP1 gene changes and  plasma cell morphology and BCL1 expression. High grade 
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plasma cells (P=0.020) (Table 3) and BCL1 expression (P=0.012) go with additional 
copies of FOXP1 locus.  
DISCUSSION 
Results obtained on 13 MGUS and 60 MM samples showed FOXP1 protein expression 
in both plasma cell neoplasm. FOXP1 gene aberrations are similar in MGUS and MM – 
in both groups there are no translocations; only additional copies of the gene could be 
found. Some difference between MGUS and MM could be suspected because of 
amplification (5 and more FOXP1 copies) in MM and only one additional FOXP1 copy in 
MGUS. As differentiation between amplification and aneuploidy was not done, we can 
not assume if there is only gene amplification and not chromosome 3 gain. Whatever the 
cause is, it seems that more FOXP1 gene copies represent some trigger for its protein 
expression, although significant χ2 value between additional FOXP1 gene copies and 
FOXP1 protein expression was not shown. 
In MGUS, statistically, no significant χ2 result was shown. 
In MM, statistics linked FOXP1 gene aberrations to diffuse type of bone marrow 
infiltration, higher plasma cell grade and expression of BCL1 protein. Additional FOXP1 
gene copies or chromosome 3 gain, thus come with advanced stage of disease or 
maybe just more complex intracellular events in a tumor plasma cell at the beginning of 
the disease. 
Our data gained on relatively small groups of patients indicate FOXP1 presence and 
involvement in plasma tumor cells development. As normal plasma cells do not express 
FOXP1 protein, it could be assumed that FOXP1 is important for B-cell differentiation 
and that final B-cell, plasma cell, does not require FOXP1 for its function.  Therefore, our 
findings about FOXP1 presence in MM and MGUS may point out direction of plasma cell 
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changes in MM: tumor cells might regress or they might originate from B-cell stage that 
has a stop in development just before final plasma cell is produced. Further studies for 
analyzing possible value of these findings in treatment of MM patients are required as 
well as in other malignancies as suggested by Koon et al in 2007. 13 
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Figure 1. Bone marrow sections of multiple myeloma patients with a) non diffuse 
infiltration pattern, b) diffuse infiltration pattern and bone marrow aspirate smears with c) 
low grade and d) high grade morphology of tumor plasma cells. 
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Figure 2. JC12 immunohistochemical positivity based on peroxidase reaction in a) 
monoclonal gammopathy of undetermined significance and b) multiple myeloma cases. 
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Table 1. Immunohistochemical findings and genetic aberrations data (detected by FISH 
method) of multiple myeloma and monoclonal gammopathy of undetermined 
significance patients. 
 
 
multiple 
myeloma   
monoclonal gammopathy of undetermined 
significance  
Σ 60 13 
 + - NI† + - NI 
BCL1 expression 23 37 0 5 8 0 
PAX5 (BSAP) 
expression 
3 57 0 0 13 0 
CD20 expression 11 49 0 5 8 0 
del(13) 4 22 34 0 4 9 
IGH/BCL1 9 51 0 2 11 0 
IGH/FGFR3 19 40 1 1 12 0 
IGH/MAF 4 55 1 0 13 0 
IGH/c-MYC 13 44 3 1 11 1 
PAX5 translocation 12 43 5 2 11 0 
†NI (not informative) – cases which were not analysed because  
of a lack of material or cases that were uninterpretable due to  
low sample quality 
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Table 2. Summarized JC12 immunostaining and FOXP1 gene aberrations data for 13 
monoclonal gammopathy of undetermined significance and 60 multiple myeloma 
patients. 
  multiple myeloma  monoclonal gammopathy of 
undetermined significance 
Σ  60 13 
+ 12 1 FOXP1 protein 
expression† - 48 12 
 
 
 
FOXP1 gene 
changes 
 
 
 
 
 
20 with one 
additional copy; 
1 with two additional 
copies; 
3 with ≥5 copies; 
36 without changes 
 
 
 
5 with one additional copy; 
8 without changes 
 
 
†
 >30% of neoplastic plasma cells positive by immunohistochemistry with JC12 antibody 
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Table 3. Chi-square test between bone marrow infiltration pattern and myeloma cell 
grading of 60 multiple myeloma patients in relation to FOXP1 protein expression and 
FOXP1 gene changes. 
   FOXP1 protein 
expression 
χ
2
 
FOXP1 gene 
changes  
χ
2
 
diffuse  21 bone marrow 
infiltration non-diffuse 39 
0.242 
(P=0.622) 
12.777 
(P=0.000) 
low  44 grading of 
tumor cell 
morphology 
high 16 
0.392 
(P=0.822) 
7.864 
(P=0.020) 
 
Figure 1. Bone marrow sections of multiple myeloma patients with a) non diffuse 
infiltration pattern, b) diffuse infiltration pattern and bone marrow aspirate smears with c) 
low grade and d) high grade morphology of tumor plasma cells. 
 
 
 
 
 
Figure 2. JC12 immunohistochemical positivity based on peroxidase reaction in a) 
monoclonal gammopathy of undetermined significance and b) multiple myeloma cases. 
 
 
